drugset / Trial / NCT02166177

Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients

NCT02166177

NaSingle-groupOpen-labelTreatment

Summary

'ThRIL' aims to explore the feasibility, safety and efficacy of TR002, a regulatory cell therapy, as adjunct immunosuppressive treatment in the context of liver transplantation

Timeline

Start
2014-06
Primary completion
2018-01-22
Completion
2018-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous regulatory T Cell Product Cell therapy Intravenous
Background Sirolimus Small molecule
Background Tacrolimus Small molecule
Background Thymoglobulin Protein / enzyme biologic

Indications